CELL COMPOSITIONS AND METHODS FOR CANCER THERAPY

• US 20190330303A1
• Filed: 05/20/2019
• Published: 10/31/2019
• Est. Priority Date: 01/09/2014
• Status: Active Grant

• Current Assignee: Hadasit Medical Research Services & Development Ltd (Hadassah, The Women's Zionist Organization of America, Inc.)
• Original Assignee: Hadasit Medical Research Services & Development Ltd (Hadassah, The Women's Zionist Organization of America, Inc.)
• Inventors: RUTENBERG, Abraham, UZANA, Ronny, LOTEM, Michal, MACHLENKIN, Arthur, EISENBERG, Galit, PERETZ-YABLONSKY, Tamar, FRANKENBURG, Shoshana, ENGELSTEIN, Roni
• Granted Patent: US 11,530,251 B2
• Time in Patent Office: Days
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2039/876 Skin, melanoma
• CPC Class Codes: A61K 2239/57 Skin; melanoma
• CPC Class Codes: A61K 35/17 Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes when activated by a specific antigen A61K39/00
• CPC Class Codes: A61K 38/1774 Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
• CPC Class Codes: A61K 39/39 characterised by the immunostimulating additives, e.g. chemical adjuvants
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61K 39/4611 T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
• CPC Class Codes: A61K 39/464491 Melan-A/MART
• CPC Class Codes: A61K 39/464492 Glycoprotein 100 [Gp100]
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07K 14/70503 Immunoglobulin superfamily
• CPC Class Codes: C07K 16/2803 against the immunoglobulin superfamily
• CPC Class Codes: C07K 2317/75 Agonist effect on antigen
• CPC Class Codes: C12N 2501/2302 Interleukin-2 (IL-2)
• CPC Class Codes: C12N 2501/998 Proteins not provided for elsewhere
• CPC Class Codes: C12N 5/0638 Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]

Abstract

The present invention is directed to the field of immunotherapy. Specifically, the invention provides compositions and methods for improved T cell modulation ex vivo and in vivo and for the treatment of cancer and other pathologies. More specifically, embodiments of the invention are directed to the use of soluble NTB-A polypeptides or agonists thereof for the treatment of cancer patients, for preventing and treating cytopenia in susceptible patients, and for the ex vivo preparation of improved cell compositions.

Claims

1-66. -66. (canceled)

67. A method of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an isolated NTB-A ectodomain or an agonist thereof, wherein said subject is afflicted with a tumor selected from the group consisting of:

a tumor characterized by lack of substantial NTB-A surface expression, a solid tumor and a tumor characterized by surface expression of CD137.

68. The method of claim 67, wherein said subject is afflicted with a tumor characterized by lack of substantial NTB-A surface expression.

69. The method of claim 67, wherein the NTB-A ectodomain is human NTB-A ectodomain.

70. The method of claim 67, wherein the agonist is an antibody specific to an NTB-A ectodomain.

71. The method of claim 67, wherein the NTB-A ectodomain further comprises an epitope tag and/or a serum half-life elongating substance.

72. The method of claim 67, wherein said subject is a cytopenic subject, or a subject at risk of developing cytopenia.

73. The method of claim 67, wherein IL-2 is not exogenously administered to said subject.

74. The method of claim 67, further comprising administering to said subject a CD137 ligand or an agonist thereof.